EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Tapan M Kadia iD, Alex Bataller iD, Alexandre Bazinet iD, Gautam Borthakur iD, Naval Daver, Nicholas J Short, Courtney DiNardo, Elias Jabbour, Caitlin R Rausch iD, Ghayas C Issa, Naveen Pemmaraju, Maro Ohanian und 18 weitere

American Journal of Hematology · 2026-07 · 101 (7) · 1737-1747

DOI: 10.1002/ajh.70328 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 25.04.2026. Verfasst von Tapan M Kadia und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax‐based low‐intensity regimens have improved the outcomes of older or unfit patients with acute myeloid leukemia (AML). This phase II study investigated the combination of cladribine plus low‐dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for older or unfit patients with newly diagnosed AML. A total of 190 patients were included; the median age was 68 years (range, 47–84 years; 13% ≥ 75 years). By the European LeukemiaNet 2022 classification, 16%, 20%, and 64% were stratified as favorable, intermediate, and adverse risk, respectively. The rates of complete remission (CR)/CR with incomplete blood count recovery (CRi) and minimal residual disease (MRD) negative CR/CRi were 84% and 75% overall and 91% and 77% among patients with TP53 ‐wild type AML, respectively. The 4‐ and 8‐week mortality rates were 1% and 3%, respectively. Among responders, 44% proceeded to allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) and event free survival (EFS) were 52 and 50 months, respectively. The 2‐ and 5‐year OS rates were 60% and 45%, respectively. The 2‐and 5‐year EFS rates were 56% and 43%, respectively. Patients achieving MRD‐negative CR had a median OS not reached and a 2‐year OS rate of 70%. The median time to absolute neutrophil count recovery (> 1 × 10 9 /L) and platelet count recovery (> 100 × 10 9 /L) after induction was 27 and 24 days, respectively. Overall, the treatment was safe and most grade 3 and 4 adverse events were infectious complications. The combination produced a high rate of remissions, translating into favorable outcomes for older patients with newly diagnosed AML. Trial Registration: ClinicalTrials.gov idetifier: NCT03586609

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteAgedAged, 80 and overFemaleHumansMaleMiddle AgedAzacitidineBridged Bicyclo Compounds, HeterocyclicCladribineCytarabineHematopoietic Stem Cell TransplantationRemission InductionSulfonamides

Substanzen

AzacitidineBridged Bicyclo Compounds, HeterocyclicCladribineCytarabineSulfonamidesvenetoclax

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Tapan M Kadia, Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Caitlin R Rausch, Koji Sasaki, Ian M Bouligny, Musa Yilmaz, Uday Popat, Farhad Ravandi

Förderung

  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Kadia, T. M., Bataller, A., Bazinet, A., Borthakur, G., Daver, N., Short, N. J., DiNardo, C., Jabbour, E., Rausch, C. R., Issa, G. C., Pemmaraju, N., Ohanian, M., Maiti, A., Montalban-Bravo, G., Sasaki, K., Bouligny, I. M., Yilmaz, M., Haddad, F. G., Masarova, L., …, & Kantarjian, H. M. (2026). Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. American Journal of Hematology, 101(7), 1737-1747. https://doi.org/10.1002/ajh.70328

Vancouver

Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, et al. Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. American Journal of Hematology. 2026;101(7):1737-1747. doi:10.1002/ajh.70328

BibTeX
@article{Kadia2026,
  author = {Kadia, Tapan M and Bataller, Alex and Bazinet, Alexandre and Borthakur, Gautam and Daver, Naval and Short, Nicholas J and DiNardo, Courtney and Jabbour, Elias and Rausch, Caitlin R and Issa, Ghayas C and Pemmaraju, Naveen and Ohanian, Maro and Maiti, Abhishek and Montalban-Bravo, Guillermo and Sasaki, Koji and Bouligny, Ian M and Yilmaz, Musa and Haddad, Fadi G and Masarova, Lucia and Chien, Kelly and Alvarado, Yesid and Jain, Nitin and Popat, Uday and Shpall, Elizabeth and Loghavi, Sanam and Qiao, Wei and Wang, Xuemei and Garcia-Manero, Guillermo and Ravandi, Farhad and Kantarjian, Hagop M},
  title = {Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {7},
  pages = {1737--1747},
  doi = {10.1002/ajh.70328}
}
Kostenlos starten →